Med BioGene Corporate Announcements; Scott Davis, CGA Replaces David Matthews as Chief Financial Officer
Published: Dec 14, 2010
VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 13, 2010) - Med BioGene Inc. (TSX VENTURE: MBI) today made two corporate announcements.
MBI announced the appointment of Scott Davis, CGA, as Chief Financial Officer in replacement of David Matthews. Mr. Davis is a partner of Cross Davis & Company LLP Certified General Accountants, a firm focused on providing accounting and management contract services for publicly-listed companies.
MBI also announced that, as part of its cost reduction efforts, it has ceased its engagement of Kilmer Lucas Inc. to provide MBI with investor relations and corporate communications services.
About Med BioGene
MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests. MBI is committed to advancing personalized medicine by commercializing tests that provide clinically relevant information to improve patient treatment and reduce health care costs. For more information, please visit www.medbiogene.com.
Certain statements in this press release contain forward-looking information and statements ("forward-looking statements") under applicable Canadian and United States securities legislation. Words such as "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements include, but are not limited to, that with respect to the timing, completion and/or results of clinical trials or studies, future profits, future product revenues, future operations and plans, the completion and use of proceeds from financings and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements are only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. MBI's forward-looking statements do not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking statements are qualified in their entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.
LungExpress Dx is MBI's trademark. Each trademark, trade name or service mark of any other entity appearing in this news release belongs to its holder.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For corporate information, please contact:
Med BioGene Inc.
Erinn B. Broshko, Chief Executive Officer
For investor relations information, please contact: